CD7 and non-Hodgkin lymphoma: Recently, two clinical trials using CD7-specific CAR-T cells were launched to assess the safety and efficacy in the patients with CD7+ NK/T cell lymphoma (NCT04004637) and T-NHL (NCT04033302), respectively.